T1	Participants 102 132	familial adenomatous polyposis
T2	Participants 237 287	patients with familial adenomatous polyposis (FAP)
T3	Participants 752 764	FAP patients
T4	Participants 433 496	genotypically positive but phenotypically negative FAP patients
T5	Participants 1044 1055	41 patients
T6	Participants 1628 1658	patients treated with sulindac
T7	Participants 1186 1211	sulindac-treated patients
T8	Participants 1371 1391	patients on sulindac
